KR100253748B1 - 신규 치환된 살리실산 - Google Patents

신규 치환된 살리실산 Download PDF

Info

Publication number
KR100253748B1
KR100253748B1 KR1019940701664A KR19940701664A KR100253748B1 KR 100253748 B1 KR100253748 B1 KR 100253748B1 KR 1019940701664 A KR1019940701664 A KR 1019940701664A KR 19940701664 A KR19940701664 A KR 19940701664A KR 100253748 B1 KR100253748 B1 KR 100253748B1
Authority
KR
South Korea
Prior art keywords
compound
compounds
salts
hydroxy
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019940701664A
Other languages
English (en)
Korean (ko)
Inventor
칼 휴버트 아가백
리프 알그렌
토마스 베르그린드흐
마틴 하랄드쏜
라스-인게 올쏜
고란 스메데가르
Original Assignee
아그네타 시그리드 탠너펠트 ; 니클라스 포르스룬트
카비 파마시아 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아그네타 시그리드 탠너펠트 ; 니클라스 포르스룬트, 카비 파마시아 에이비 filed Critical 아그네타 시그리드 탠너펠트 ; 니클라스 포르스룬트
Application granted granted Critical
Publication of KR100253748B1 publication Critical patent/KR100253748B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1019940701664A 1991-11-18 1992-11-04 신규 치환된 살리실산 Expired - Fee Related KR100253748B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9103397-7 1991-11-18
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (1)

Publication Number Publication Date
KR100253748B1 true KR100253748B1 (ko) 2000-05-01

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940701664A Expired - Fee Related KR100253748B1 (ko) 1991-11-18 1992-11-04 신규 치환된 살리실산

Country Status (29)

Country Link
US (3) US5302718A (enExample)
EP (1) EP0613468B1 (enExample)
JP (1) JP3259915B2 (enExample)
KR (1) KR100253748B1 (enExample)
AT (1) ATE194597T1 (enExample)
AU (1) AU668528B2 (enExample)
CA (1) CA2123697C (enExample)
DE (1) DE69231252T2 (enExample)
DK (1) DK0613468T3 (enExample)
EE (1) EE03026B1 (enExample)
ES (1) ES2149780T3 (enExample)
FI (1) FI106857B (enExample)
GR (1) GR3034585T3 (enExample)
HU (2) HU221476B (enExample)
IL (1) IL103665A (enExample)
LT (1) LT3182B (enExample)
LV (1) LV10246B (enExample)
MX (1) MX9206647A (enExample)
MY (1) MY130169A (enExample)
NO (1) NO300805B1 (enExample)
NZ (1) NZ244998A (enExample)
PT (1) PT101068B (enExample)
RU (1) RU2124501C1 (enExample)
SE (1) SE9103397D0 (enExample)
SK (1) SK282080B6 (enExample)
TW (1) TW304944B (enExample)
UA (1) UA42869C2 (enExample)
WO (1) WO1993010094A1 (enExample)
ZA (1) ZA928864B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
AU717230B2 (en) 1996-02-20 2000-03-23 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
JP2003520758A (ja) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のｒｘｒモジュレーターを用いた処置
HK1039778A1 (zh) 1999-03-19 2002-05-10 Bristol-Myers Squibb Company 制造联苯异恶唑基磺胺的方法
ES2273725T3 (es) 1999-09-04 2007-05-16 Astrazeneca Ab Derivados de hidroxiacetamidobencenosulfonamida.
MY127036A (en) 1999-09-04 2006-11-30 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
ES2307528T3 (es) 1999-09-04 2008-12-01 Astrazeneca Ab Amidas como inhibidores para la piruvato deshidrogenasa.
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
EP1278521B1 (en) * 2000-04-28 2005-11-30 The University of British Columbia N-heterocyclic substituted salicylates for the treatment of cancer
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
KR100360342B1 (ko) * 2002-04-19 2002-11-13 박계정 밸런스 머신의 언밸런스 수정위치 및 수정량의 자동 보상방법
WO2005023771A1 (ja) * 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
JP2007514731A (ja) * 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物
WO2006003517A1 (en) * 2004-06-29 2006-01-12 Warner-Lambert Company Llc Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
EP1991530A1 (en) * 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
KR20110027648A (ko) * 2008-06-23 2011-03-16 아스테라스 세이야쿠 가부시키가이샤 술폰아미드 화합물 또는 이의 염
WO2012116170A1 (en) * 2011-02-23 2012-08-30 Ming-Ming Zhou Inhibitors of bromodomains as modulators of gene expression
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
DE69231252D1 (de) 2000-08-17
LT3182B (en) 1995-03-27
UA42869C2 (uk) 2001-11-15
PT101068B (pt) 1999-08-31
IL103665A0 (en) 1993-04-04
LTIP229A (en) 1994-09-25
WO1993010094A1 (en) 1993-05-27
NO941799D0 (no) 1994-05-13
US5556855A (en) 1996-09-17
JP3259915B2 (ja) 2002-02-25
HU221476B (en) 2002-10-28
JPH07501330A (ja) 1995-02-09
US5403930A (en) 1995-04-04
DK0613468T3 (da) 2000-10-23
US5302718A (en) 1994-04-12
HUT69723A (en) 1995-09-28
SK282080B6 (sk) 2001-10-08
ES2149780T3 (es) 2000-11-16
MY130169A (en) 2007-06-29
LV10246A (lv) 1994-10-20
RU2124501C1 (ru) 1999-01-10
CA2123697A1 (en) 1993-05-27
HU9401391D0 (en) 1994-08-29
SK54794A3 (en) 1995-02-08
FI106857B (fi) 2001-04-30
FI942289L (fi) 1994-05-17
EP0613468B1 (en) 2000-07-12
HU211163A9 (en) 1995-10-30
CA2123697C (en) 2003-12-09
IL103665A (en) 1997-08-14
MX9206647A (es) 1993-05-01
NO300805B1 (no) 1997-07-28
ZA928864B (en) 1993-05-13
LV10246B (en) 1995-04-20
EP0613468A1 (en) 1994-09-07
SE9103397D0 (sv) 1991-11-18
NZ244998A (en) 1995-09-26
GR3034585T3 (en) 2001-01-31
FI942289A0 (fi) 1994-05-17
EE03026B1 (et) 1997-08-15
TW304944B (enExample) 1997-05-11
PT101068A (pt) 1994-02-28
NO941799L (enExample) 1994-06-22
DE69231252T2 (de) 2001-03-01
AU668528B2 (en) 1996-05-09
AU2958992A (en) 1993-06-15
ATE194597T1 (de) 2000-07-15

Similar Documents

Publication Publication Date Title
KR100253748B1 (ko) 신규 치환된 살리실산
EP2855467B1 (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
EP2855466B1 (en) Processes to produce certain 2-(pyridine-3-yl)thiazoles
CA1103246A (en) Thiazine derivatives
RU2086542C1 (ru) Серосодержащие производные имидазола, способ их получения, новые промежуточные соединения и фармацевтическая композиция
JPS5951536B2 (ja) ピリジン誘導体の製法
US3923810A (en) Perfluoroalkanesulfonamides N-substituted by heterocyclic groups
NO302887B1 (no) Sakkarinderivater med proteolytisk enzyminhiberende aktivitet, farmasöytisk preparat inneholdende slike derivater samt anvendelse derav
NO770161L (no) Tiazolidinderivater og fremgangsm}te til deres fremstilling.
US3337576A (en) Arylthioalkyltetrazoles
RU2069212C1 (ru) Производные имидазола
US3542779A (en) New 4-quinazolone derivatives and process for the preparation thereof
JPS6325584B2 (enExample)
PT94904A (pt) Processo para a preparacao de derivados benzotiazinicos e de composicoes farmaceuticas que os contem
JPH06211819A (ja) ベンジリデン誘導体
JPS61267542A (ja) アミノベンズアミド化合物
CZ287285B6 (cs) Nové substituované salicylové kyseliny
JP2022041821A (ja) 血小板凝集抑制剤、その製造方法及び使用
DK151012B (da) Analogifremgangsmaade til fremstilling af 3-methyl-4-halogen-5-aminooxymethyl-isoxazoler eller et syreadditionssalt deraf
JPS62270566A (ja) １，２，４−トリアゾリン−５−オン誘導体及びその製造方法
JPS63192762A (ja) ２−アリ−ル−４−ハロメチル−４−イソオキサゾリン−３−オン誘導体
HU214705B (hu) 2-(Klór, bróm vagy nitro)-4-szulfinil-benzoesav származékok és eljárás előállításukra
BR112017019116B1 (pt) Método para preparar composto de sulfonamida de alta pureza e intermediário do composto de sulfonamida
JPH07267924A (ja) プログルメタシンの製造方法
JPS6126537B2 (enExample)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20051230

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20070127

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20070127